Eray Goekkurt
Eray Goekkurt has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Anke Reinacher-Schick
Department for Hematology, Oncology and Palliative Care, St Josef-Hospital, Ruhr-University Bochum, Bochum, Germany
31 shared publications - Annabel Helga Sophie Alig
Department of Hematology, Oncology, and Cancer Immunology, Charité - Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
22 shared publications - Annika Kurreck
Charité-Universitätsmedizin Berlin 9 Department of Hematology, Oncology, and Cancer Immunology Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
22 shared publications - Arndt Stahler
Department of Hematology, Oncology and Cancer Immunology (CCM), Charité - Universitaetsmedizin Berlin, Corporate Member of Freie Universitaet Berlin and Humboldt-Universitaet zu Berlin, Berlin, Germany
22 shared publications - Dominik Paul Modest
Department of Hematology, Oncology, and Cancer Immunology (CVK/CCM), Charité-Universitätsmedizin Berlin, Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
22 shared publications - Sebastian Stintzing
Department of Hematology, Oncology and Cancer Immunology, Charité—Universitaetsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
22 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 2: Emotional distress and tumor burden do not explain the systemic inflammatory signature.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 2: Emotional distress and tumor burden do not explain the systemic inflammatory signature.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 4: PFS in selected patients and overall survival of NLR > 5 patients. (A) PFS in months is shown for patients selected by CPS ≥ 1, HER2-3+, and NLR < 5 within the Ipi arm (n=12). Median PFS was 20.9 months. (B) Final overall survival is shown for the Ipi vs FOLFOX arm of NLR >5 preselected patients. Number of patients at risk are indicated. Log-rank test was performed (B).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 4: PFS in selected patients and overall survival of NLR > 5 patients. (A) PFS in months is shown for patients selected by CPS ≥ 1, HER2-3+, and NLR < 5 within the Ipi arm (n=12). Median PFS was 20.9 months. (B) Final overall survival is shown for the Ipi vs FOLFOX arm of NLR >5 preselected patients. Number of patients at risk are indicated. Log-rank test was performed (B).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 3: Low NLR defines patients with superior survival in the Ipi arm.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 3: Low NLR defines patients with superior survival in the Ipi arm.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 1: The duration of response to various therapy lines for patients in the Ipi arm is depicted. For each line of therapy, the duration of response (DOR) is indicated if applicable. Active therapy is represented by an arrow, and dashed arrows are used for patients who were lost to follow-up. Monotherapy with trastuzumab (T), ramucirumab (R), radiotherapy (#), or surgery (*) is also indicated.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Inflammatory Stress Determines the Need for Chemotherapy in Patients with HER2-Positive Esophagogastric Adenocarcinoma Receiving Targeted Therapy and Immunotherapy
Supplementary Figure 1: The duration of response to various therapy lines for patients in the Ipi arm is depicted. For each line of therapy, the duration of response (DOR) is indicated if applicable. Active therapy is represented by an arrow, and dashed arrows are used for patients who were lost to follow-up. Monotherapy with trastuzumab (T), ramucirumab (R), radiotherapy (#), or surgery (*) is also indicated.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Overview of antibodies used for staining and cutoffs in TMA analysis.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Overview of antibodies used for staining and cutoffs in TMA analysis.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Analysis of overall survival within the maintenance therapy set by high/low immune expression, tumor region and treatment arm.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Analysis of overall survival within the maintenance therapy set by high/low immune expression, tumor region and treatment arm.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Risk analysis of Overall Response Rates in the epithelial tumor of tumor center and invasive margin in the Maintenance set by treatment arm.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
Risk analysis of Overall Response Rates in the epithelial tumor of tumor center and invasive margin in the Maintenance set by treatment arm.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S11 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
P, Odds Ratios and 95% Confidence Intervals regarding ORR of immunoexpression in the epithelial tumor in the tumor center and the invasive margin after exclusion of cases with BRAF V600E and MSI – Maintenance Set.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S11 from Spatial Tumor Immune Microenvironment as a Prognostic and Predictive Biomarker in Anti–EGFR-Based Maintenance for RAS wt Metastatic CRC—The PanaMa (AIO KRK0212) Trial
P, Odds Ratios and 95% Confidence Intervals regarding ORR of immunoexpression in the epithelial tumor in the tumor center and the invasive margin after exclusion of cases with BRAF V600E and MSI – Maintenance Set.